Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer
- 1 September 2006
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 1 (7) , 635-647
- https://doi.org/10.1097/01243894-200609000-00007
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung AdenocarcinomasClinical Cancer Research, 2005
- Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancerCurrent Oncology Reports, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerJournal of Cellular Physiology, 2005
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- The ErbB/HER receptor protein-tyrosine kinases and cancerBiochemical and Biophysical Research Communications, 2004
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline InhibitorJournal of Biological Chemistry, 2002
- Genetic polymorphisms and lung cancer susceptibility: a reviewLung Cancer, 2002
- TherasOncogenes in Human Lung CancerAmerican Review of Respiratory Disease, 1990